Investor Presentation • Oct 6, 2016
Investor Presentation
Open in ViewerOpens in native device viewer
Oct. 6th, 7th 2016
Certain statements in this slide show, including those addressing the Company's beliefs, plans, objectives, estimates or expectations of possible future results or events, are forward-looking statements. Forward-looking statements involve known or unknown risks, including general economic and business conditions, and conditions in the industry we operate and may be affected should our assumptions turn out to be inaccurate. Consequently, no forward-looking statement can be guaranteed and actual future results, performance, or achievements may vary materially from those expressed or implied by such forward-looking statements. The Company undertakes no obligation about the contents nor to update the forward-looking statements to reflect events or circumstances that may arise after the date hereof.
www.elengroup.com
| \$ l b l k f d l l b d h h ( l l ) i i i G 2 0 1 9 t t o a m a r e o r m e c a a s e r s y e n u s e r o u g m o n s , |
|||||||||
|---|---|---|---|---|---|---|---|---|---|
| 2 0 1 3 |
2 0 1 4 |
C A G % R |
|||||||
| 2 0 1 4 2 0 1 9 - |
|||||||||
| 7 5 8 |
8 1 3 |
1 2 1 9 |
% 8 4 , |
||||||
| 8 9 5 |
0 2 1 4 |
2 0 9 7 |
% 1 5 4 , |
||||||
| 2 0 9 |
2 4 4 |
6 2 3 |
2 0 % 7 , |
||||||
| 9 9 |
1 1 5 |
2 4 7 |
1 6 % 5 , |
||||||
| 1 9 6 1 |
2 1 9 5 |
4 1 8 5 |
1 3 8 % , |
||||||
| 2 0 1 9 |
Global market for medical lasers by region, through 2019 (\$ millions)
| k M S t t a r e e g m e n |
2 0 1 3 |
2 0 1 4 |
2 0 1 9 |
% C A G R |
|
|---|---|---|---|---|---|
| 2 0 1 4 2 0 1 9 - |
|||||
| d d U S C a n a n a a |
9 0 2 |
1 0 0 8 |
1 8 7 0 |
1 3 2 % , |
|
| E u r o p e |
5 7 9 |
6 4 7 |
1 2 0 8 |
% 1 3 3 , |
|
| f i i i A P s a a c c |
3 5 2 |
3 9 9 |
8 4 9 |
% 1 6 3 , |
|
| h O t e r |
2 8 1 |
1 4 1 |
2 8 5 |
2 8 % 1 , |
|
| l T t o a |
9 6 1 1 |
2 9 1 5 |
8 4 1 5 |
3 8 % 1 , |
| l B V a e y u |
l b l G M o a a |
k ( l i E U R M t r e |
( ) C A G R % |
||
|---|---|---|---|---|---|
| 2 0 1 3 |
2 0 1 6 |
2 0 2 0 |
2 0 1 3 2 0 1 6 - |
2 0 1 6 2 0 2 0 - |
|
| C i t t n u g |
2 4 0 8 |
3 0 1 4 |
3 9 6 5 |
7 8 , |
7 1 , |
| l d d i i W B e n g a n r a n g z |
1 2 4 9 |
1 6 0 5 |
2 2 3 1 |
8 7 , |
8 6 , |
| f d h S O t t t t u r a c e r e a m e n a n e r |
5 0 |
6 3 |
8 6 |
8 3 , |
8 1 , |
| l T t o a |
3 7 0 7 |
4 6 8 2 |
6 2 8 2 |
8 1 , |
7 6 , |
High –Tech laser photonics Group
Develops, manufactures and distributes laser sources and laser systems for medical and industrial applications
Know-how based on 35 years stratification of multidisciplinary experience
FY 2015: Consolidated Revenues of €218 mln, up 21% YoY H1 2016: Consolidated Revenues of €120 mln, up 12% YoY
1042 employees
Global positioning
Combine High tech laser source development with flexible production facilities in high growth areas
Technological and clinical innovation improving performance andbroadening the application scope of our laser systems
Cynosure
IRR= 32,50%Capital Gain = €92 mln
Clinical trials and validations of new therapeutic laser treatments and research on new applications of laser- tissue interaction
Broadening Mona Lisa Touch Clinical studiesNew Pico second laser platform Clinical studies on cutaneous ulcers Painless laser hair removalPatents developmentIncreased power of RF laser sourcesInnovative applications for mid power laser systems
| / E 0 0 0 r o u |
/ / 3 0 0 6 1 5 |
/ / 3 0 0 6 1 6 |
% V a r. |
||
|---|---|---|---|---|---|
| R e e n e s v u |
1 0 6 8 8 4 |
1 0 0 0 % , |
1 2 0 1 7 6 |
1 0 0 0 % , |
1 2 4 % , |
| i G r o s s m a r g n |
8 0 4 7 7 |
% 4 5 0 , |
3 2 6 5 4 |
% 4 4 3 , |
% 1 0 8 , |
| E B I T D A |
1 2 5 2 9 |
% 1 1 7 , |
1 5 5 6 7 |
3 0 % 1 , |
2 2 % 4 , |
| E B I T |
1 0 3 7 4 |
% 9 7 , |
1 3 5 2 4 |
% 1 1 3 , |
% 3 0 4 , |
| P I t r e a x n c o m e |
1 1 6 9 4 |
% 1 0 9 , |
3 5 9 7 9 |
% 2 9 9 , |
% 2 0 7 7 , |
| i N t e n c o m e |
7 6 2 3 |
1 % 7 , |
3 0 2 9 3 |
2 2 % 5 , |
2 9 4 % 7 , |
| h N I t e n c o m e p e r s a r e |
0 0 4 , |
1 5 7 , |
|||
| / E 0 0 0 u r o |
/ / 3 1 1 2 1 5 |
/ / 3 0 0 6 1 6 |
% V a r. |
|---|---|---|---|
| 9 7 7 6 6 |
6 0 0 3 4 |
% 3 9 - |
|
| 9 8 6 1 5 |
9 3 2 3 5 |
1 % - |
|
| 2 9 8 1 5 |
0 8 0 7 1 |
3 % 1 7 |
|
| 9 0 4 7 |
8 0 8 7 |
1 0 % |
|
| i N E t t e q u y |
1 7 9 5 3 9 |
1 8 1 4 5 1 |
% 1 |
| 1 4 9 7 2 4 |
1 1 0 6 5 0 |
% 2 6 - |
|
| 2 8 % |
2 5 % |
||
| O C R E |
% 1 4 |
2 % 4 |
|
| C a p e x |
8 2 4 3 |
4 5 1 1 |
|
Total non current assetsNet Working CapitalNet financial positionLong term liabilitiesNet capital employed
Net Working Capital on sales
(EBIT/Net capital employed)
Sales 2016 = Sales 2015 +10%-> €239 mln
EBIT 2016 = EBIT 2015 +15%-> €25 mln
www.elengroup.com
El.En. S.p.A.
| k h l 's h d i S E t t o c o e r q u y p e r s a r e |
9 | |
|---|---|---|
| / k l d i j. P B V A r c e o o a u e |
2 1 , |
|
| / ( ) 8 % E V E B I T 5 E B I T |
2 1 1 , |
|
| / ( ) l l V S 8 % S E 5 a e s a e s |
1 4 , |
|
| l. k C E E M t n a r e a p |
3 9 @ € 8 6 5 1 1 1 , , |
|
| f i i l i i N t t e n a n c a p o s o n |
/ / 0 8 @ 3 0 0 6 1 6 7 , |
|
| / i i l i l F t t t n a n c a n e s m e n s m e r m v |
/ / 1 0 7 @ 3 0 0 6 1 6 , |
|
| l i E V t n e r p r s e a u e |
2 7 7 6 , |
|
| k h l d 's i f i i i S E t t t t o c o e r q u y n e o m n o r e s |
/ / 1 2 0 @ 3 0 0 6 1 6 7 , |
| June 30th, 2016 | Price | Revenue | Var.% Revenue |
EBIT | EBIT% | MK.Cap. | ${\sf EV}$ | EV/Sales $(*)$ |
EV/EBIT $(*)$ |
$P/E (*)$ | P/Book Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Medical/Aesthetic | |||||||||||
| Syneron | \$7,16 | \$143.663 | 5% | \$1.558 | 1% | \$257.150 | \$188.798 | 0,7 | 60,6 | 261,9 | 1,2 |
| Zeltiq | \$39,22 | \$153.934 | 33% | \$(14.690) | $-10%$ | \$1.590.000 | \$1.537.930 | 5,0 | n.a. | n.a. | 14,0 |
| Cutera | \$11,92 | \$49.900 | 20% | \$ (3.587) | $-7%$ | \$158.280 | \$114.958 | 1,2 | n.a. | n.a. | 3,3 |
| Biolase | \$1,75 | \$24.820 | 9% | \$(7.700) | $-31%$ | \$103.340 | \$98.337 | 2,0 | n.a. | n.a. | 5,5 |
| Cynosure | \$50,94 | \$205.007 | 29% | \$14.951 | 7% | \$1.220.000 | \$1.027.811 | 2,5 | 34,4 | 66,4 | 2,8 |
| Industrial | |||||||||||
| IPG Photonics Co. | \$82,35 | \$460.035 | 6% | \$165.027 | 36% | \$4.420.000 | \$3.705.920 | 4,0 | 11,2 | 19,0 | 3,1 |
| Rofin-Sinar | \$32,18 | \$236.490 | $-7%$ | \$18.139 | 8% | \$915.230 | \$737.471 | 1,6 | 20,3 | 38,2 | 1,6 |
| Prima Industrie | €13,74 | €183.291 | 4% | €7.083 | 4% | €144.040 | €248.182 | 0,7 | 17,5 | 24,6 | 1,1 |
| ELEn. (1) | €18,61 | €120.176 | 12% | €13.524 | 11% | €359.126 | €277.582 | 1,4 | 12,1 | 9,4 | 2,1 |
| (1) EV and multiplies as for previous slide () Revenue, Ebit and earnings annualized (*) w/o one time income |
$23,1$ (**) |
Enrico ROMAGNOLI Investor Relations Managertel. +39 055-8826807E-mail: [email protected]
Bianca FERSINI MASTELLONI Financial CommunicationTel. +39 06-6797849 / +39 06-69923324E-mail: [email protected]
Silvia MARONGIUPress officeTel. +39 06-6797849 / +39 06-69923324E-mail: [email protected]
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.